California Doctor Loses DEA License, Can't Prescribe Controlled Drugs
Published Date: 6/10/2025
Notice
Summary
Dr. Harry Kram from California lost his DEA registration because he no longer has permission to handle controlled substances in his state. Despite being notified, he didn’t ask for a hearing, so the DEA officially revoked his registration by default. This means Dr. Kram can’t legally prescribe or handle controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked — Dr. Kram
Dr. Harry Kram (DEA Certificate No. AK1539444) has had his DEA registration revoked effective July 10, 2025. This revocation means he cannot legally prescribe, dispense, or handle controlled substances, which prevents him from providing those aspects of medical care and will affect his medical practice and related income.
Pending DEA Applications Denied in California
The DEA denied any pending applications by Harry Kram, M.D., to renew or modify his registration and denied any pending applications for additional registration in California. That denial accompanies the final order effective July 10, 2025, and prevents him from obtaining DEA registration while he lacks state authority to practice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-10500, Marine Mammals; File No. 28712
Dr. Kaitlin Allen from Woods Hole Oceanographic Institution got a special permit to import, export, and study marine mammal parts for science until June 2035. This helps researchers learn about how marine mammals dive, breathe, and reproduce without harming endangered species. The permit follows all the rules and won’t hurt the environment or protected animals.
Next: 2025-10502, Serge Menkin, M.D.; Decision and Order
Dr. Serge Menkin from New Jersey lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of January 31, 2025. This means Dr. Menkin can’t legally work with controlled drugs anymore, and the decision is final.